Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

3.72
-0.0400-1.06%
Pre-market: 3.870.1500+4.03%06:40 EDT
Volume:572.86K
Turnover:2.14M
Market Cap:247.75M
PE:-3.25
High:3.81
Open:3.78
Low:3.70
Close:3.76
52wk High:15.74
52wk Low:2.83
Shares:66.60M
Float Shares:41.99M
Volume Ratio:0.41
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1445
EPS(LYR):-1.1819
ROE:-27.10%
ROA:-18.36%
PB:0.74
PE(LYR):-3.15

Loading ...

Fulcrum Therapeutics 10% Owner Kevin Tang Acquires $594,132 of Common Shares

Reuters
·
Jul 21

Fulcrum Therapeutics 10% Owner Kevin Tang Reports Buying $892,170 of Common Shares

Reuters
·
Jul 16

Fulcrum Therapeutics Director Alan Ezekowitz Disposes of 18,000 Common Shares for $65,614

Reuters
·
Jul 01

Fulcrum Therapeutics Shareholders Reaffirm Board and Governance Structure

TIPRANKS
·
Jun 26

Fulcrum Therapeutics Shareholders Elect Banks, Ezekowitz, Hill as Directors

Reuters
·
Jun 26

Fulcrum Therapeutics Advances Restructuring with Leadership Changes

TIPRANKS
·
Jun 12

Fulcrum Therapeutics offers CEO cash retention payment of $370,040 tied to change in control

Reuters
·
Jun 12

Ratings Weekly|Meta, Microsoft, IBM, CoreWeave, Lululemon and More to Watch

Tiger Newspress
·
Jun 07

BUZZ-Fulcrum down after announcing restructuring, plans to cut 85% jobs

Reuters
·
Jun 05

Fulcrum Therapeutics Undertakes Major Restructuring, Explores Strategic Alternatives

TIPRANKS
·
Jun 05

Fulcrum Therapeutics to Cut Most of Staff After Ending Sickle-Cell-Drug Development

Dow Jones
·
Jun 05

Fulcrum Therapeutics - to Reduce Workforce by 85% From 57 to 9 Employees, Completion Expected Q2 2026 - SEC Filing

THOMSON REUTERS
·
Jun 05

Fulcrum Therapeutics - Approves Restructuring Plan After Discontinuing Pociredir for Sickle Cell Disease - SEC Filing

THOMSON REUTERS
·
Jun 05

Fulcrum Therapeutics - Expects Aggregate Restructuring Charges of About $4.2 Mln - SEC Filing

THOMSON REUTERS
·
Jun 05

Fulcrum Therapeutics cuts workforce 85% in restructuring plan

Reuters
·
Jun 05

What's Going On With Fulcrum Therapeutics Stock On Thursday?

Benzinga_recent_news
·
Jun 04

Analysts’ Top Healthcare Picks: Fulcrum Therapeutics (FULC), ADC Therapeutics (ADCT)

TIPRANKS
·
Jun 04

JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight

MT Newswires Live
·
Jun 03

Why Fulcrum Therapeutics (FULC) Is Down 53.6% After Ending Pociredir And Exploring Strategic Options

Simply Wall St.
·
Jun 03

Fulcrum Therapeutics Inc : JP Morgan Cuts to Underweight From Overweight

THOMSON REUTERS
·
Jun 03